Pancreatic Adenocarcinoma Clinical Trials in Chicago, Illinois

6 studies are recruiting for pancreatic adenocarcinoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope, Chicago, Illinois

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

2. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

   Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tel…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   46 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT05365581 on ClinicalTrials.gov

3. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07621718 on ClinicalTrials.gov

4. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 124, Chicago, Illinois

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

5. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

6. Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

   The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to make 5-FU work well).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT04361708 on ClinicalTrials.gov